Making use of autologous pericardium when options, and reconstruction references, are few
There are no easy solutions for acute infective tricuspid valve endocarditis in IV drug users, as the risk of prosthetic endocarditis in this population is high. Complete valve resection without replacement is feasible but leads to progressive right-sided heart failure. Reconstruction of the tricuspid valve with autologous pericardium is an alternative option, as demonstrated in the video case study below.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A 29-year-old female drug abuser with fever, hemoptysis and MRSA bacteremia was started on IV antibiotics. She looked frail and had prominent jugular venous pressure as well as 95 percent saturation on 2 liters of nasal cannula oxygen. She was not on inotropes and had a pulmonary artery pressure of 40/20 mmHg with a good cardiac index. Chest CT showed a large left pleural effusion with associated atelectasis of the left lung. The right lung had manifestations of septic emboli and a smaller pleural effusion.
A Cleveland Clinic surgical team led by cardiothoracic surgeon Faisal Bakaeen, MD, proceeded to excise the patient’s extensive infected and devitalized tissue around the tricuspid valve, leaving only a portion of the anterior leaflet to serve as a reference for reconstruction using autologous pericardium. Dr. Bakaeen walks us through the essential surgical steps — and their underlying rationale — in the narrated operative video below.
Video content: This video is available to watch online.
View video online (https://www.youtube.com/embed/9jbBhExzuU4?feature=oembed)
Advertisement
Advertisement
Lower threshold expanded revascularization candidacy without raising early complication rates
Elevated levels of the gut microbial metabolite predict prevalence and adverse outcomes in community-based study
They generally depend on the mutated gene, clone size and clinical setting
Large analysis adds to evidence that absolute diameter alone may miss vulnerable patients
Procedure places the center among only a handful worldwide to offer the minimally invasive approach
Phase 1 trial shows up to 97% decrease through 48 weeks with good tolerability
Post hoc ALPACA analysis boosts biological rationale for ongoing outcomes trial of lepodisiran
Durability findings propel potential one-time treatment approach to phase 1b testing